Larazotide

Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide

A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge

The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial

The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases

The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate

Larazotide acetate: a pharmacological peptide approach to tight junction regulation

The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis

Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment

Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms

Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats

Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series

Tight junction regulation in celiac disease: role of larazotide acetate

Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation

Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions

In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model

Effects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats

In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate

The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats

[Larazotide as an option in case of failure of a gluten-free diet]

AT-1001 Is a Partial Agonist with High Affinity and Selectivity at Human and Rat α3β4 Nicotinic Cholinergic Receptors

Functional characterization of AT-1001, an α3β4 nicotinic acetylcholine receptor ligand, at human α3β4 and α4β2 nAChR

High affinity α3β4 nicotinic acetylcholine receptor ligands AT-1001 and AT-1012 attenuate cocaine-induced conditioned place preference and behavioral sensitization in mice

AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology

Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001

Commentary: larazotide acetate - an exciting new development for coeliac patients?

Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply

Larazotide acetate promotes tight junction assembly in epithelial cells

Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials

Larazotide acetate regulates epithelial tight junctions in vitro and in vivo

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse.

Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis.

Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier.